恩格列净对糖尿病伴夜间高血压患者的24小时降压效果:SACRA随机安慰剂对照研究
恩格列净较基线显著降低夜间收缩压6.3 mmHg,但组间差异未达统计学显著(-4.3 mmHg,P=0.159);日间、24小时、晨间家庭及诊室收缩压降幅均显著大于安慰剂。
要点
- 恩格列净较基线显著降低夜间收缩压6.3 mmHg,但组间差异未达显著。
- 日间、24小时、晨间家庭及诊室收缩压降幅均显著优于安慰剂。
- 体重和糖化血红蛋白降幅虽显著但幅度小,NT-proBNP 4周时降幅更大。
核心结论
- 在已接受包括ARB在内的稳定降压治疗的2型糖尿病伴未控制夜间高血压老年患者中,加用恩格列净可显著降低血压,且不依赖大幅降糖。
研究设计与样本
- 患者随机接受恩格列净10 mg每日一次或安慰剂治疗12周,基线及12周行24小时动态血压监测。
主要发现
- 恩格列净较基线显著降低夜间收缩压(-6.3 mmHg,P=0.004),组间变化差异为-4.3 mmHg(P=0.159)。
- 恩格列净较安慰剂显著降低日间、24小时、晨间家庭及诊室收缩压(分别-9.5、-7.7、-7.5、-8.6 mmHg,均P≤0.002)。
- 恩格列净组体重和糖化血红蛋白降幅显著但较小(组间差-1.3 kg和-0.33%,均P<0.001)。
- 4周时恩格列净组NT-proBNP降幅大于安慰剂(-12.1%,P=0.013);4周和12周ANP较安慰剂降低(-8.2%[P=0.008]和-9.7%[P=0.019])。
- 研究期间降压药物调整两组间无显著差异。
临床怎么用
- 对于已接受稳定ARB治疗的2型糖尿病伴未控制夜间高血压老年患者,加用恩格列净可能有助于降低24小时血压。
- 恩格列净的降压作用不能仅归因于降糖效果,在特定人群(如夜间高血压、糖尿病、高盐敏感性)中可能有助于降低心衰和心血管死亡风险。
局限性
- 夜间收缩压组间差异未达统计学显著(P=0.159)。
- 研究人群为非重度肥胖、老年、血糖控制良好的日本患者,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The risk of cardiovascular disease and mortality in salt-sensitive patients with diabetes mellitus and uncontrolled nocturnal hypertension is high. The SACRA (Sodium-Glucose Cotransporter 2 [SGLT2] Inhibitor and Angiotensin Receptor Blocker [ARB] Combination Therapy in Patients With Diabetes and Uncontrolled Nocturnal Hypertension) study investigated changes in blood pressure (BP) with empagliflozin plus existing antihypertensive therapy. METHODS: This multicenter, double-blind, parallel study was conducted in Japan. Adult patients with type 2 diabetes mellitus and uncontrolled nocturnal hypertension receiving stable antihypertensive therapy including angiotensin receptor blockers were randomized to 12 weeks' treatment with empagliflozin 10 mg once daily or placebo. Clinic BP was measured at baseline and weeks 4, 8, and 12; 24-hour ambulatory BP monitoring was performed at baseline and week 12; and morning home BP was determined for 5 days before each visit. The primary efficacy end point was change from baseline in nighttime BP (ambulatory BP monitoring). RESULTS: One hundred thirty-two nonobese, older patients with well-controlled blood glucose were randomized (mean age 70 years, mean body mass index 26 kg/m2). Empagliflozin, but not placebo, significantly reduced nighttime systolic BP versus baseline (-6.3 mm Hg; P=0.004); between-group difference in change from baseline was -4.3 mm Hg (P=0.159). Reductions in daytime, 24-hour, morning home, and clinic systolic BP at 12 weeks with empagliflozin were significantly greater than with placebo (-9.5, -7.7, -7.5, and -8.6 mm Hg, respectively; all P≤0.002). Between-group differences in body weight and glycosylated hemoglobin reductions were significant, but small (-1.3 kg and -0.33%; both P<0.001). At 4 weeks, N-terminal pro-B-type natriuretic peptide levels were reduced to a greater extent in the empagliflozin versus placebo group (-12.1%; P=0.013); atrial natriuretic peptide levels decreased with empagliflozin versus placebo at weeks 4 and 12 (-8.2% [P=0.008] and -9.7% [P=0.019]). Changes in antihypertensive medication during the study did not differ significantly between groups. CONCLUSIONS: Nonseverely obese older diabetes patients with uncontrolled nocturnal hypertension showed significant BP reductions without marked reductions in glucose with the addition of empagliflozin to existing antihypertensive and antidiabetic therapy. Use of sodium-glucose cotransporter 2 inhibitors in specific groups (eg, those with nocturnal hypertension, diabetes, and high salt sensitivity) could help reduce the risk of heart failure and cardiovascular mortality. CLINICAL TRIAL REGISTRATION: URL: https://www. CLINICALTRIALS: gov. Unique identifier: NCT03050229.
引用
- Kario K, Okada K, Kato M, et al. Twenty-Four-Hour Blood Pressure-Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension: Results From the Randomized, Placebo-Controlled SACRA Study. Circulation. 2018. PMID: 30586745. doi:10.1161/CIRCULATIONAHA.118.037076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。